Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.
CMS innovation center to expand team focused on drug prices
To help with new pilot models aimed at lowering drug costs across Medicaid and Medicare, CMS’ innovation center is ramping up staff. “We are on



